November 8, 2025American Journal of Preventive Cardiology1 citationsOpen Access
View Full PaperProteomic predictors of mortality among people with Coronary Artery Disease
Key Result
A proteomics score derived from mortality-associated proteins enriched in inflammation and cellular adhesion pathways was developed and validated to predict all-cause mortality in patients with CAD.
Study Design
Type
Cohort (n=2,859)
Multicenter
Yes
Structured PICO
Does a proteomics score predict all-cause mortality in people with Coronary Artery Disease?
P
Population
2,859 participants with Coronary Artery Disease (CAD) from two independent cohorts (n=2,768 from the UK Biobank and n=91 from the Mental Stress Ischemia Prognosis Study).
I
Intervention
Proteomic profiling and derivation of a proteomics score using LASSO-selected proteins
O
Outcome
All-cause mortalityhard clinical
A proteomics score based on inflammation and cellular adhesion pathways may enhance prognostic precision for all-cause mortality in patients with coronary artery disease.
Abstract
Background: Coronary artery disease (CAD) continues to pose a significant global health challenge, highlighting the crucial need to enhance prognostic accuracy and improve mortality outcomes for CAD management. Proteomics offers a nuanced perspective on the molecular intricacies underlying CAD progression. This study investigates proteomic profiles in people with CAD, aiming to identify protein markers associated with mortality outcomes. Methods: Utilizing the UK Biobank (UKB) and the Mental Stress Ischemia Prognosis Study (MIPS), the study analyzed proteomic data from 2768 CAD participants in the UKB and 91 CAD participants in the MIPS. Cox proportional hazards models, LASSO regression, and pathway enrichment analysis were employed to identify proteomic predictors of all-cause mortality. A proteomics score was derived using the LASSO-selected proteins. Results: ). Mortality-associated proteins revealed enrichment in pathways related to inflammation and cellular adhesion. Conclusion: This study expands our understanding of CAD prognosis by uncovering potential proteomic biomarkers. The development and validation of the proteomics score in two independent CAD cohorts in the UK and the US underscore the potential utility for enhancing prognostic precision in the context of CAD.